MCL Literature Feed

This review clarifies that cyclin D1-negative MCL is driven by CCND2 or CCND3 translocations, proposing new terminology to improve diagnostic accuracy for this rare and often missed subtype.

Real-world data show BTKi refractoriness and poor in-vivo brexu-cel expansion predict worse survival, identifying high-risk patients for early relapse and highlighting CAR-T kinetics as a key biomarker.

This review advocates for using prognostic tools like MIPI and TP53 status to guide risk-adapted therapy in MCL, intensifying for high-risk and de-escalating for low-risk patients.

A novel Mcl1-degrading AUTAC compound synergizes with proteasome inhibitors by hijacking the adaptive autophagy response, offering a preclinical strategy to overcome proteasome inhibitor resistance in MCL.

This case report of late, recurrent neurotoxicity after brexucabtagene autoleucel demonstrates a mechanism of direct CNS infiltration by CAR-T cells, highlighting the need for long-term vigilance.

A novel electrochemical sensor was developed for highly sensitive bortezomib detection, potentially enabling therapeutic drug monitoring to personalize dosing and manage toxicity in MCL patients.

A rare case of MCL transdifferentiating into a clonally-related T-cell lymphoma demonstrates a novel transformation mechanism where B-cell markers are lost, complicating diagnosis at relapse.

This review highlights stereotyped B-cell receptors in MCL, suggesting common antigen-driven pathways that could provide a basis for molecular subclassification to refine patient risk stratification.

This methods paper details using sensitive qPCR and ddPCR to detect MRD in B-cell lymphomas by targeting Ig gene rearrangements and chromosomal translocations, relevant for MCL's t(11;14).

The Australasian Lymphoma Alliance provides consensus guidelines for MCL diagnosis and management, integrating novel therapies and risk-stratification using biomarkers like TP53, blastoid morphology, and high Ki67.

This study confirms that low/negative CD200 and lower CD43 expression by flow cytometry reliably distinguish MCL from CLL, improving routine diagnostic accuracy for B-cell lymphoproliferative disorders.

Bioinformatic analysis reveals a positive correlation between STING expression and cytolytic score in MCL, suggesting STING may be a biomarker for immune activity and a potential immunotherapy target.

The novel agent Ironomycin induces MCL cell death by targeting iron metabolism addiction, identifying a potential new therapeutic strategy based on a metabolic vulnerability.

This case report identifies a novel jumping translocation of 3q in an MCL patient, linking this rare cytogenetic event to clonal evolution and a potential poor prognosis.

This pediatric pathology study is not relevant to mantle cell lymphoma; it repurposes the BCL-1/Cyclin D1 IHC stain to diagnose Hirschsprung disease, a non-malignant gastrointestinal disorder.

Preclinical Galectin-9 induces cell death in MCL cell lines by disrupting autophagy, a novel, apoptosis-independent mechanism to potentially overcome chemoresistance.

This case report demonstrates CNS relapse in an MCL patient with a low Ki-67 (10%), underscoring the need for CSF analysis in symptomatic patients regardless of proliferation index.

This review outlines the potential of AI-based PET/CT radiomics to improve lymphoma diagnosis and prognosis, but its specific clinical application in MCL remains undefined pending further research.

A novel MIPI/CD3 prognostic model using Quantitative Dot Blot to measure T-cell infiltration improves risk stratification, showing high CD3+ T-cells correlate with better outcomes in MCL.

This CLL study reveals venetoclax rapidly activates a BAFF-driven survival axis in residual tumor cells, a key resistance mechanism potentially targetable in MCL to deepen BCL2i responses.

Epigenetic profiling reveals a unique DNA methylation signature for B-cell prolymphocytic leukemia, providing a novel biomarker to differentiate it from its mimics, including mantle cell lymphoma.

This case report illustrates the diagnostic challenge of distinguishing mantle cell lymphoma from chronic lymphocytic leukemia, emphasizing the critical role of specific pathological and cytogenetic markers for accurate diagnosis.

In newly diagnosed MCL, PET/CT-based bone marrow assessment has greater prognostic value than biopsy and is incorporated into a new MCL-PET-I index for improved risk stratification.

This review highlights that TP53-mutated MCL represents a distinct high-risk entity with poor outcomes to chemoimmunotherapy, underscoring the urgent need for novel, non-chemotherapy frontline approaches in these patients.

This review confirms MRD's strong prognostic value in MCL but cautions that technical limitations and the uncertain clinical significance of low-level disease currently prevent its routine use for treatment decisions.

Analysis of European MCL Network trial data shows specific gene mutations predict patient outcomes, providing a genetic basis for risk stratification to guide therapy selection beyond clinical scores.

Quantitative measurement of Cyclin D1 protein reveals that higher levels are paradoxically associated with better overall survival, establishing a novel, independent prognostic biomarker for MCL risk stratification.

A novel αCD20-EndoP125A antibody fusion protein inhibits MCL growth and dissemination in preclinical models by disrupting tumor-vessel interactions, including angiogenesis, lymphangiogenesis, and vessel co-option.

Malignant effusions, frequently caused by blastoid MCL, are characterized by a T/B cell ratio <1, providing a crucial diagnostic marker from cytological samples.

Preclinically, bortezomib-induced apoptosis depends exclusively on the protein NOXA, which inactivates both MCL-1 and BCL-XL, providing a refined understanding of its mechanism and potential resistance.